CARA vs. UNCY, NXTC, LEXX, EYEN, SNSE, BOLT, NBRV, VYNE, IMRX, and XLO
Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Unicycive Therapeutics (UNCY), NextCure (NXTC), Lexaria Bioscience (LEXX), Eyenovia (EYEN), Sensei Biotherapeutics (SNSE), Bolt Biotherapeutics (BOLT), Nabriva Therapeutics (NBRV), VYNE Therapeutics (VYNE), Immuneering (IMRX), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.
Cara Therapeutics (NASDAQ:CARA) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.
Cara Therapeutics received 646 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. Likewise, 74.94% of users gave Cara Therapeutics an outperform vote while only 64.29% of users gave Unicycive Therapeutics an outperform vote.
Cara Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500.
44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 4.2% of Cara Therapeutics shares are owned by insiders. Comparatively, 42.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Unicycive Therapeutics has lower revenue, but higher earnings than Cara Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cara Therapeutics currently has a consensus price target of $9.75, suggesting a potential upside of 1,262.49%. Unicycive Therapeutics has a consensus price target of $5.30, suggesting a potential upside of 369.03%. Given Cara Therapeutics' higher probable upside, equities analysts plainly believe Cara Therapeutics is more favorable than Unicycive Therapeutics.
Unicycive Therapeutics has a net margin of 0.00% compared to Cara Therapeutics' net margin of -565.21%. Unicycive Therapeutics' return on equity of 0.00% beat Cara Therapeutics' return on equity.
In the previous week, Cara Therapeutics had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 5 mentions for Cara Therapeutics and 3 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.73 beat Cara Therapeutics' score of 0.55 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.
Summary
Unicycive Therapeutics beats Cara Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Cara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cara Therapeutics Competitors List
Related Companies and Tools
